Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: Ductal carcinoma in situ (DCIS) of the breast is one of the most common pre-invasive cancers diagnosed in women. Quality of life (QoL) is extremely important to assess in studies including these patients due to the favorable prognosis of the disease. The primary objective of this systematic review was to compile a comprehensive list of QoL issues, all existing QoL assessment tools, and patient-reported outcome measures used to assess DCIS.
Methods: A search was conducted on Ovid MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials databases from inception to August 2023, using keywords such as "ductal carcinoma in-situ", "quality of life", and "patient-reported outcomes." QoL issues and QoL tools in primary research studies were extracted.
Results: A total of 67 articles identified issues pertaining to patients with DCIS spanning physical, functional, and psychosocial QoL domains. Physical and functional issues observed in patients included pain, fatigue, and impaired sexual functioning. Psychosocial issues such as anxiety, depression, and confusion about one's disease were also common. QoL tools included those that assessed general QoL, breast cancer-specific tools, and issue-specific questionnaires.
Conclusion: The current instruments available to assess QoL in patients with DCIS do not comprehensively capture the issues that are pertinent to patients. Thus, the modification of existing tools or the creation of a DCIS-specific QoL tool is recommended to ensure that future research will be sensitive towards challenges faced by patients with DCIS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00520-024-08864-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Do Patients with DCIS or Invasive Breast Cancer Carry the Same Risk for Genetic Mutation?
Ann Surg Oncol
September 2025
Saint John's Cancer Institute, Providence Saint John's Health Center, Santa Monica, CA, USA.
Implications of the COMET Trial for the Management of Atypical Ductal Hyperplasia.
Ann Surg Oncol
September 2025
Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Background: The recently reported results from the COMET trial investigating the nonoperative management of low-risk ductal carcinoma in situ (DCIS) question the need for routine excision of atypical ductal hyperplasia (ADH). This study aimed to examine the upgrade rates of patients with ADH who met applicable COMET trial criteria.
Methods: Cases of ADH managed with surgery at our institution between 2004 and 2022 were identified, and clinical variables were extracted from the medical record.
Feasibility and Prognostic Analysis of Neoadjuvant Therapy Followed by Breast-Conserving Surgery for Invasive Ductal Carcinoma Combined with Ductal Carcinoma in Situ.
J Invest Surg
December 2025
Department of General Surgery, Hebei Province Hospital of Chinese Medicine, Affiliated Hospital of Hebei University of Chinese Medicine, Shijiazhuang, China.
Objective: This study aim to investigate the oncological safety of neoadjuvant therapy (NAT) followed by breast-conserving surgery (BCS) for invasive ductal carcinoma (IDC) patients with the presence of ductal carcinoma (DCIS) on pre-NAT biopsy.
Methods: The data of women with IDC who underwent radical surgery between January 2013 and December 2021 were retrospectively reviewed from two institutions. The study endpoints were 5-year disease-free survival (DFS) and local recurrence-fee survival (LRFS).
Breast Cancer Incidence Among Patients Undergoing Chest Masculinization Surgery: A Scoping Review.
Ann Surg Oncol
August 2025
Department of Plastic Surgery, University of Virginia School of Medicine, Charlottesville, VA, USA.
Background: The incidence of breast cancer (BC) cases among transgender males undergoing gender-affirming mastectomy (GAM) and the future BC risk for this population are not well established. This scoping review aimed to explore breast cancer incidence rates before and after GAM in the United States.
Methods: Following the Arskey and O'Malley framework, the search was conducted in Embase and PubMed using keywords "gender-affirming surgery" and "breast cancer.
Prevalence of Incidental Breast Cancer and Precursor Lesions in Carriers of Pathogenic Germline Variants Undergoing Risk-Reducing Mastectomy.
Anticancer Res
September 2025
HBOC-Center, Department of Gynecology with Breast Center, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Berlin, Germany.
Background/aim: Precursor lesions, including B3 lesions of uncertain malignant potential, preinvasive lesions such as ductal carcinoma (DCIS), and invasive lesions identified in the breast tissue of carriers of pathogenic germline variants undergoing risk-reducing breast surgery, have received limited attention to date. This study aimed to assess the prevalence and histopathological features of these lesions, considering their genetic, demographic, and radiological characteristics.
Patients And Methods: We performed a retrospective monocentric cohort study analyzing 169 healthy women and patients after previous breast cancer who carried pathogenic germline variants in , and .